ReShape Lifesciences Inc. (OBLN) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Cash flows from operating activities:
Net loss	-61.9	-21.6
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	0.2	0.0		0.6	0.3
Amortization of intangible assets	1.7	1.7
(Gain) loss on disposal of assets, net			0.1	0.1		0.0	0.0	0.0
Stock-based compensation	12.8	1.3	3.0	4.7	3.2	0.6	0.2	0.2
Bad debt expense	0.1	0.3
Deferred income tax	-0.1	-0.1
Gain on changes in fair value of liability warrants	2.8				1.6	0.5	0.0	-0.2
Other noncash items		0.0
Change in operating assets and liabilities, net of business combination:
Accounts and other receivables	-0.3	1.2	0.6	3.4	-4.2		0.1	0.1
Inventory	-0.4	-1.2	0.0	-0.2	-0.6	-0.5	0.1	-0.2
Prepaid expenses and other current assets	-0.4	0.8	0.4	0.1	-0.5	-1.0	0.0	-0.1
Accounts payable and accrued liabilities	-1.5	-1.0	-3.5	-0.6	2.6	1.3	1.4
Warranty liability	-0.7	0.1
Other	0.5	0.1
Net cash used in operating activities	-15.4	-8.6	-22.9	-29.4	-30.6	-19.4	-11.4	-9.9

Cash flows from investing activities:
Proceeds from sale of capital assets							0.0
Cash (used in) provided by investing activities:	1.9	-2.4	2.4	19.5	-21.9	6.2	2.8	-7.9

Cash flows from financing activities:
Proceeds from sale and issuance of securities			23.4	9.8		67.2
Proceeds from warrants exercised	45.6	0.7
Net cash provided by financing activities	33.3	11.1	13.4	10.0	0.6	82.8	5.1	22.2
Effect of currency exchange rate changes on cash and cash equivalents	0.0	-0.1

Proceeds from issuance of common stock warrant liabilities, net of issuance costs of $1,442
Noncash investing and financing activities:
Capital expenditures accruals	0.0	0.2	0.0	0.2	0.1	0.1